Can India’s Syngene Best WuXi?
This article was originally published in PharmAsia News
Executive Summary
Syngene's initial public offering (IPO) opened for subscription in India on 27 July, amid generally encouraging reviews and favorable comparisons with China's WuXi PharmaTech. Syngene is part of the Indian firm Biocon, and like WuXi provides a range of contract research services to the pharma industry.